• 1. Evolutionary approaches in protein engineering towards biomaterial construction
  Brindha J.,Balamurali M. M.,Kaushik Chanda RSC Adv., 2019,9, 34720-34734
• 2. Fatty acid eutectic mixtures and derivatives from non-edible animal fat as phase change materials?
  Pau Gallart-Sirvent,Marc Martín,Gemma Villorbina,Mercè Balcells,Aran Solé,Luisa F. Cabeza,Ramon Canela-Garayoa RSC Adv., 2017,7, 24133-24139
• 3. Fate of nitrogen-15 in the subsequent growing season of greenhouse tomato plants (Lycopersicon esculentum Mill) as influenced by alternate partial root-zone irrigation
  Maomao Hou,Fenglin Zhong,Qiu Jin,Enjiang Liu,Jie Feng,Tengyun Wang,Yue Gao RSC Adv., 2017,7, 34392-34400
• 4. Evolution and characterization of a benzylguanine-binding RNA aptamer?
  J. Xu,T. J. Carrocci,A. A. Hoskins Chem. Commun., 2016,52, 549-552
• 5. Evolutionary de novo design of phenothiazine derivatives for dye-sensitized solar cells?
  Vishwesh Venkatraman,Marco Foscato,Vidar R. Jensen,Bj?rn K?re Alsberg J. Mater. Chem. A, 2015,3, 9851-9860

Introduction to 6-O-Desmethyl Donepezil-d5 and Its Significance in Modern Medicinal Chemistry

The compound with the CAS no. 1189443-74-0, known as 6-O-Desmethyl Donepezil-d5, represents a critical derivative in the field of pharmaceutical chemistry. This deuterated analog of Donepezil, a well-known acetylcholinesterase inhibitor used primarily for the treatment of Alzheimer's disease, offers unique advantages in both research and clinical applications. The introduction of deuterium atoms at specific positions enhances the compound's metabolic stability and provides valuable insights into its pharmacokinetic behavior.

6-O-Desmethyl Donepezil-d5 is particularly significant in the context of drug metabolism and pharmacokinetic (DMPK) studies. The presence of deuterium atoms disrupts the metabolic pathways, making it an ideal tool for investigating the enzymatic processes involved in drug degradation. This has been increasingly relevant in recent years, as researchers strive to develop more efficient and targeted therapies for neurodegenerative disorders. The compound's stability under various metabolic conditions allows for precise tracking of its degradation products, which is essential for understanding its overall bioavailability and efficacy.

In the realm of medicinal chemistry, 6-O-Desmethyl Donepezil-d5 serves as a benchmark for developing new acetylcholinesterase inhibitors. The deuterated version not only retains the pharmacological activity of its parent compound but also offers improved analytical detection due to the enhanced mass spectrometry fragmentation patterns. This has been particularly useful in clinical trials and biomarker studies, where sensitive detection methods are crucial for monitoring drug efficacy and patient response.

Recent advancements in mass spectrometry techniques have further highlighted the importance of 6-O-Desmethyl Donepezil-d5 in drug development. Researchers have leveraged these techniques to study the compound's interactions with biological targets at a molecular level. This has led to a deeper understanding of how acetylcholinesterase inhibitors modulate neural activity, providing new avenues for therapeutic intervention. For instance, studies using 6-O-Desmethyl Donepezil-d5 have revealed insights into the compound's binding affinity and duration of action, which are critical parameters for optimizing drug design.

The pharmaceutical industry has also embraced 6-O-Desmethyl Donepezil-d5 as a key intermediate in the synthesis of novel acetylcholinesterase inhibitors. Its structural integrity and metabolic stability make it an excellent candidate for further chemical modifications. By incorporating this derivative into synthetic pathways, chemists can explore new chemical entities with enhanced pharmacological properties. This approach aligns with the growing trend toward personalized medicine, where tailored drug formulations are designed to meet individual patient needs.

From a regulatory perspective, 6-O-Desmethyl Donepezil-d5 has played a pivotal role in ensuring compliance with safety and efficacy standards. Regulatory agencies often require detailed pharmacokinetic data before approving new drugs, and 6-O-Desmethyl Donepezil-d5 provides comprehensive information on metabolic pathways and drug interactions. This has expedited the approval process for several acetylcholinesterase inhibitors, benefiting patients who rely on these medications for managing neurodegenerative conditions.

The future prospects of 6-O-Desmethyl Donepezil-d5 are promising, with ongoing research exploring its potential applications beyond Alzheimer's disease treatment. Studies suggest that this derivative may have therapeutic benefits in other neurological disorders, such as Parkinson's disease and cognitive impairment associated with aging. Additionally, its role in biomarker discovery is being explored, as researchers seek to identify reliable indicators of drug response and toxicity.

In conclusion, 6-O-Desmethyl Donepezil-d5 (CAS no. 1189443-74-0) is a cornerstone in modern medicinal chemistry, offering invaluable insights into drug metabolism, pharmacokinetics, and therapeutic development. Its unique properties make it an indispensable tool for researchers and clinicians alike, driving advancements in the treatment of neurodegenerative diseases and beyond. As our understanding of complex biological systems continues to evolve, compounds like 6-O-Desmethyl Donepezil-d5 will remain at the forefront of pharmaceutical innovation.

• 120013-56-1(6-O-Desmethyl Donepezil)
• 120013-57-2(5-O-Desmethyl Donepezil)
• 845252-34-8(Donepezil impurity C)
• 120014-06-4(Donepezil)
• 197010-20-1(Hydroxy Donepezil(Mixture of Diastereomers))
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)